The Prevention of Colitis by E Prostanoid Receptor 4 Agonist through Enhancement of Epithelium Survival and Regeneration
- 1 January 2007
- journal article
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 320 (1) , 22-28
- https://doi.org/10.1124/jpet.106.111146
Abstract
Inflammatory bowel disease (IBD) is often triggered and/or exacerbated by nonsteroidal anti-inflammatory drugs (NSAIDs). Among various prostanoids affected by NSAIDs, prostaglandin E2 (PGE2), in particular, seems to play critical roles in IBD via the EP4 receptor, one of the four PGE2 receptor subtypes (EP1–4). An EP4 agonist, [[3-[[(1R,2S,3R)-3-hydroxy-2-[(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]-1-butenyl]-5-oxocyclopentyl]thio]propyl]thio]-acetic acid, C22H30O6S2 (ONO-AE1–329), for example, when topically applied, has been reported to ameliorate typical colitis symptoms by suppressing the production of cytotoxic cytokines in the dextran sodium sulfate (DSS)-induced colitis model. EP4 agonists are also known, however, for their ability to protect epithelial cells from apoptosis in vitro, which may contribute to the protection of mucosal barrier functions. To investigate this potential application, we have tested another EP4-selective agonist in the DSS-indomethacin mouse colitis model. 7-[2-(3-Hydroxy-4-phenyl-but-1-enyl)-6-oxo-piperidin-1-yl]-heptanoic acid methyl ester, C23H33NO4 (AGN205203), an analog from the 8-azapiperidinone series of EP4 agonists, is metabolically and chemically more stable than the ONO agonist, because of its lack of oxidizable sulfur atoms in the α-chain and of 11-OH group, a potential source of β-elimination reaction. Treatment of mice subcutaneously with AGN205203 at 3 mg/kg/day minimized colitis symptoms, such as weight loss, diarrhea, and colonic bleeding. Further histological examination of colons revealed healthy surface columnar epithelial cells free of erosion and ulceration compared with those without the drug treatment. At cellular level, the drug treatment decreased colon epithelial apoptosis, prevented goblet cell depletion, and promoted epithelial regeneration. AGN205203 may be unique among known EP4 agonists for its metabolic and chemical stability, and it is amenable to systemic applications for the prevention and recovery of IBD.This publication has 37 references indexed in Scilit:
- Hospitalization, Surgery, and Readmission Rates of IBD in Canada: A Population-Based StudyAmerican Journal of Gastroenterology, 2006
- EP4 Prostanoid Receptor Coupling to a Pertussis Toxin-Sensitive Inhibitory G ProteinMolecular Pharmacology, 2006
- Pharmacology and signaling of prostaglandin receptors: Multiple roles in inflammation and immune modulationPharmacology & Therapeutics, 2004
- E-Prostanoid-3 Receptors Mediate the Proinflammatory Actions of Prostaglandin E2 in Acute Cutaneous InflammationThe Journal of Immunology, 2004
- The safety profile of infliximab in patients with Crohn’s disease: The Mayo Clinic experience in 500 patientsGastroenterology, 2004
- Prostaglandin E2 aggravates gastric mucosal injury induced by histamine in rats through EP1 receptorsLife Sciences, 2003
- Prostaglandin E2 Induced Functional Expression of Early Growth Response Factor-1 by EP4, but Not EP2, Prostanoid Receptors via the Phosphatidylinositol 3-Kinase and Extracellular Signal-regulated KinasesJournal of Biological Chemistry, 2003
- A unique phenotype of 5-HT2C, agonist-induced GTPγ35S binding, transferable to 5-HT2Aand 5-HT2B, upon swapping intracellular regionsBritish Journal of Pharmacology, 2003
- Role of mucins in inflammatory bowel disease: important lessons from experimental modelsEuropean Journal of Gastroenterology & Hepatology, 2002
- Mechanisms and Modulation of Intestinal Epithelial RepairInflammatory Bowel Diseases, 2001